Premium
Contemporary narrative review of treatment options for COVID ‐19
Author(s) -
Shang Lianhan,
Lye David Chien,
Cao Bin
Publication year - 2021
Publication title -
respirology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.857
H-Index - 85
eISSN - 1440-1843
pISSN - 1323-7799
DOI - 10.1111/resp.14106
Subject(s) - medicine , hydroxychloroquine , tocilizumab , azithromycin , covid-19 , lopinavir , lopinavir/ritonavir , intensive care medicine , pandemic , ritonavir , clinical trial , randomized controlled trial , narrative review , coronavirus , disease , immunology , virology , viral load , human immunodeficiency virus (hiv) , infectious disease (medical specialty) , antibiotics , outbreak , antiretroviral therapy , biology , microbiology and biotechnology
Abstract The coronavirus disease 2019 (COVID‐19) pandemic is ongoing and many drugs have been studied in clinical trials. From a pathophysiological perspective, anti‐viral drugs may be more effective in the early stage while immunomodulators may be more effective in severe patients in later stages of infection. While drugs such as lopinavir‐ritonavir, hydroxychloroquine and azithromycin have proved to be ineffective in randomized controlled trials, corticosteroids, neutralizing monoclonal antibodies, remdesivir, tocilizumab and baricitinib have been reported to benefit certain groups of patients with COVID‐19. In this review, we will present the key clinical evidence and progress in promising COVID‐19 therapeutics, as well as summarize the experience and lessons learned from the development of the current therapeutics.